Paper Details

  1. Home
  2. Paper Details

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

Author: ColombelJ F, DescosL, FlorentC, GalmicheJ P, GendreJ P, LereboursE, MaryJ Y, ModiglianiR, SouléJ C, ViteauJ M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Slow-release mesalamine was effective in maintaining remission in Crohn's disease, particularly in patients with a high relapse risk. The 2-year ongoing remission rate was 45% in the mesalamine group compared to 29% in the placebo group.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mesalamine provides a new therapeutic approach in treating Crohn's disease. METHODS: To assess the efficacy and safety of slow-release mesalamine (Pentasa; Ferring AS, Vanløse, Denmark) in maintaining remission in Crohn's disease, 161 patients with inactive disease were randomized to re...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0016-5085(93)90411-5

データ提供：米国国立医学図書館（NLM）

Maintaining Remission in Crohn's Disease: A New Hope with Mesalamine

This research ventures into the field of inflammatory bowel diseases, specifically focusing on Crohn's disease. The study investigates the efficacy of oral mesalamine (Pentasa) in maintaining remission, a crucial aspect of managing this chronic condition. The study employs a randomized, placebo-controlled trial, a rigorous approach to assess the effectiveness of a treatment compared to a sham intervention.

A New Path to Remission: Exploring the Efficacy of Mesalamine

The study shows that Pentasa is effective in maintaining remission in Crohn's disease, particularly in patients who achieved remission within 3 months. This finding provides valuable insights into the potential benefits of mesalamine for managing this debilitating disease. It's like finding a refreshing oasis in the desert, offering relief and hope for patients struggling with Crohn's disease.

Navigating the Desert of Crohn's Disease

The study highlights the importance of early intervention and maintenance therapy in Crohn's disease. It provides evidence that Pentasa can be a valuable tool in managing this chronic condition and improving quality of life for patients. This knowledge is like a guide through the desert, leading us to a better understanding of Crohn's disease and its management.

Dr. Camel's Conclusion

This research offers a beacon of hope for patients with Crohn's disease. By demonstrating the effectiveness of Pentasa in maintaining remission, the study provides valuable insights into the management of this complex condition. As researchers and clinicians, we must continue to explore new avenues for treating inflammatory bowel diseases and improving the lives of those affected by these debilitating conditions. Like a camel navigating the vast desert, we must persevere in our pursuit of knowledge and effective treatments.

Date :
  1. Date Completed 1993-02-26
  2. Date Revised 2019-07-07
Further Info :

Pubmed ID

8425685

DOI: Digital Object Identifier

10.1016/0016-5085(93)90411-5

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.